Brain
Brain Health After 60
After 60, medication review and delirium prevention deserve attention. A multivitamin produced small cognitive-test benefits, not proven dementia prevention.
Brain-health advice often focuses on what to add: another habit, another puzzle, another supplement. After 60, the less obvious questions may concern what’s already happening—in the medicine cabinet or during a hospital stay. Those parts deserve room in this Humanic Blue conversation too.
Clinical guidance supports reviewing medicines that can affect thinking and reducing delirium risk during care. Delirium is sudden, fluctuating confusion, often associated with illness or hospitalization. Multivitamin research has also found small thinking-test gains, without establishing dementia prevention or longer life. Living longer and better involves understanding those differences, alongside familiar topics such as blood pressure, hearing and activity.
Key Takeaways
- Medicines, hearing, sleep and blood-vessel health can all matter in a brain-health conversation.
- Medication-risk guidance supports individual review, not stopping prescriptions on your own.
- Hospital teams can address delirium risk; sudden confusion needs prompt assessment.
- A small supplement effect on a test isn’t evidence of preventing dementia or adding years of life.
How do the foundations fit together?
The Lancet Commission connects dementia risk with health and life circumstances. Our overview explains the list without treating it as a personal prediction.
Each part has its own purpose. Blood-pressure care addresses vessel health. Hearing care addresses communication. Exercise supports physical health, with a separate and less settled cognitive evidence base. Sleep assessment looks for a particular sleep problem.
They can belong in one conversation without their benefits adding up neatly to extra years. Nor does a birthday mean everyone needs the same new routine.
What belongs in a medicine review?
Some medicines have anticholinergic effects: they block a chemical messenger involved in several body functions, including memory. The term sounds like a specialist password, but the practical question is familiar—could a medicine be contributing to a problem?
Observational research links long-term exposure to some strongly anticholinergic medicines with higher dementia risk. That doesn’t prove the medicine caused dementia. The condition being treated and early symptoms can also affect which medicines someone receives.
The American Geriatrics Society’s guidance asks clinicians to consider the combined burden of these medicines in adults 65 and older. It supports reviewing the whole list rather than judging a drug by its category alone.
The Cochrane review of medicine reduction couldn’t establish that reducing this burden preserves thinking. A clinician or pharmacist can still investigate side effects and alternatives; stopping prescribed treatment without that discussion can create other risks.
What would make a medicine review more useful: knowing every technical name, or understanding what each medicine is for and which possible effects deserve attention?
Why does hospital confusion need attention?
Delirium can appear suddenly and fluctuate during illness, surgery or a hospital stay. It is different from a gradual memory change and shouldn’t be dismissed as ordinary aging.
A review of delirium studies found a link with later cognitive decline. It couldn’t fully separate delirium from the illness or underlying vulnerability that made it more likely.
National Institute for Health and Care Excellence (NICE) guidance recommends tailored prevention for people at risk. That can include help with knowing where they are and what is happening, familiar contact, fluids, appropriate movement, pain and medicine review, hearing or visual aids, and sleep support.
Those measures target delirium itself. Evidence that they prevent future dementia is a separate, unresolved question. NICE also encourages families to report sudden changes to the care team so the person can be assessed. Sudden confusion outside hospital likewise needs immediate medical help, as our memory guide explains.
What did the multivitamin study show?
The COSMOS research program found small thinking-test improvements with a daily multivitamin in older adults. It didn’t establish fewer dementia diagnoses, better independence or longer life.
The formulation, population and tests matter, so the result can’t be extended to every bottle on a shelf. Industry helped support the trial and supplied materials; the investigators reported that sponsors didn’t control analysis or publication decisions. Detailed results and disclosures are below.
We can understand the signal without enlarging it. A small difference on a test is a finding to investigate, not an answer to every brain-health concern. A clinician can review whether a supplement fits someone’s circumstances, including medicines and duplicate nutrients.
Which outcome would you want explained before judging a supplement claim: memory scores, daily independence, disease risk or lifespan?
What’s Interesting
Two important topics here concern care someone receives, rather than a habit they perform. Prescriptions accumulate; hospital stays happen. Brain health includes how care is organized and supported, not just whether someone remembered to do their puzzles.
What This Means in Practice
For living longer and better after 60, these sources offer questions rather than a universal regimen. What is each medicine still treating? Could side effects overlap? What delirium precautions apply during a planned stay? What outcome did a supplement study actually measure?
A primary care clinician or pharmacist can review medicines and supplements. A geriatrician can help with complex care, and new memory or daily-function difficulties need their own evaluation. The benefit of each approach depends on the problem it addresses and the person’s health.
Bottom Line
Brain health after 60 includes the medicine cabinet and the care setting as well as everyday habits. Guidance supports individual medication review and delirium prevention. Multivitamin trials report a small thinking-test improvement, with no established dementia-prevention or lifespan benefit. Those are distinct findings, not a single new prescription for aging.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01Which care question deserves more attention: medicines, hospital support or the meaning of supplement results?
- 02What would help a discussion about brain health feel manageable rather than like a new regimen?
Extra Insights & Sources
The evidence summaries and linked sources behind this article.
What We Know
- The established risk factors, including blood pressure and hearing, remain the foundation. Supported.
- Heavy, long-term use of strong anticholinergic drugs is associated with higher dementia risk. Supported (association).
- Hospital delirium is associated with later cognitive decline and dementia. Supported (association).
- A daily multivitamin modestly improved cognitive-test scores in COSMOS. Promising but clinically uncertain.
What We Don’t Know
- Whether stopping anticholinergic drugs lowers dementia risk. Unknown; that hasn’t been tested in trials.
- Whether preventing delirium prevents later dementia. Uncertain.
- Whether the multivitamin effect reduces dementia or helps people live longer. Unknown.
Delirium study details
The 2025 meta-analysis pooled 253 studies with more than 137,000 participants, average age 76. The pooled odds ratios were 1.58 for later cognitive decline and 5.37 for dementia. These are relative odds, not an individual’s probability of developing either outcome; observational studies cannot fully separate delirium from underlying illness and vulnerability.
Medication and multivitamin study details
- The English anticholinergic study included 58,769 dementia cases and 225,574 matched controls aged 55 or older. More than 1,095 standardized daily doses over the assessed 1-to-11-year exposure period were associated with an adjusted odds ratio of 1.49 compared with no exposure. An odds ratio compares odds between groups; it does not mean a 49-percentage-point increase in dementia probability. Standardized daily doses combine medicine amounts using reference doses for comparison, not a prescribed regimen for an individual.
- The Cochrane review of supervised medicine reduction (deprescribing) included three short randomized trials with 299 total participants. Serious bias and inconsistent measures left the evidence very uncertain; none measured new dementia cases.
- The COSMOS pooled analysis used nonoverlapping samples of 573 COSMOS-Clinic, 2,158 COSMOS-Mind and 2,472 COSMOS-Web participants. Overall thinking (global cognition) improved by 0.07 standard-deviation units and memory for events and experiences (episodic memory) by 0.06 standard-deviation units. These units express test-score differences on a common scale, not percentages of improvement. The overall-thinking estimate combined COSMOS-Mind and COSMOS-Clinic; the memory analysis drew from all three. These were cognitive-test outcomes, not dementia diagnoses.
COSMOS population, limits and disclosures
The parent trial enrolled US men aged 60 or older and women aged 65 or older. The cognitive studies belonged to one trial program, not three independent replications, and participants had limited racial and ethnic diversity. Results do not establish the same effect for other multivitamin formulations.
Mars Edge supported trial infrastructure. Pfizer Consumer Healthcare, now Haleon, partly supplied the multivitamin and packaging, and several investigators reported industry research support. The investigators reported that sponsors had no role in data handling, analysis or publication decisions.
Source Materials
- Coupland et al., JAMA Internal Medicine (2019) — Primary English case-control study for the 58,769 cases, 225,574 controls, exposure window, cumulative-dose result and drug-class differences. The article identifies confounding, prescription-record and causality limits.
- Dmochowski et al., Journal of Urology (2022) — Primary French nested case-control evidence for cumulative exposure and drug-specific differences among overactive-bladder anticholinergics. It supplies replication within one treatment category, not proof that the drugs caused dementia.
- 2023 American Geriatrics Society Beers Criteria — Current US expert criteria for potentially inappropriate medication use in adults 65 or older, including strongly anticholinergic medicines and cumulative burden. The criteria are a decision aid, not an automatic stop list.
- Taylor-Rowan et al., Cochrane review (2023) — Randomized evidence on anticholinergic deprescribing and cognitive outcomes. Three short, high-bias trials and 299 participants support the article’s very-low-certainty conclusion and the absence of dementia-incidence evidence.
- Tesfaye et al., Age and Ageing (2025) — Current 253-study synthesis for participant count, mean age and later cognitive-decline and dementia associations. Differences among its observational studies prevent a causal dementia-prevention conclusion.
- NICE, Delirium: Prevention, Diagnosis and Management — Current official guidance, amended in 2023, for identifying risk and delivering a tailored multicomponent prevention package in hospital and long-term care. It supports prevention steps for delirium itself.
- Vyas et al., American Journal of Clinical Nutrition (2024) — Primary COSMOS-Clinic and within-program pooled analysis for sample construction, two-year clinic outcomes, pooled standardized effects, limits, funding and conflicts. The article separates test-score changes from dementia and lifespan outcomes.
Leave a Reply